ObsEva SA

Informe acción OTCPK:OBSE.F

Capitalización de mercado: US$11.7k

ObsEva Dividendos y recompras

Dividendo controles de criterios 0/6

ObsEva no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Rendimiento de la recompra

Rendimiento total para el accionistan/a
Rendimiento futuro de los dividendosn/a
Crecimiento de los dividendosn/a
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónn/a
Ratio de pagon/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Seeking Alpha • Aug 22

ObsEva stock dips on Nasdaq non-compliance notice

ObsEva SA (NASDAQ:OBSV) received a notice from Nasdaq for failing to comply with the rule of maintaining a minimum of $10M in stockholders' equity for continued listing on the exchange. The company had disclosed in a SEC filing that as of June 30, it had shareholders' equity of ~$2.10M. ObsEva has until Aug. 29 to submit a plan to regain compliance after Nasdaq decided to provide a shortened response time to the company. The company said it intends to submit plan by the date. On July 27, ObsEva stock fell ~78% on plans to restructure following setback for uterine fibroids drug. Earlier in August, the company said it was retiring $31M in debt and had announced $11M debt refinancing. OBSV -4.13% to $0.23 premarket Aug. 22
Seeking Alpha • Aug 01

ObsEva to retire $31M in debt and announces $11M debt refinancing

ObsEva (NASDAQ:OBSV) announced the early retirement of $31M in debt partially owed to certain funds and accounts managed by JGB Management post its securities purchase agreement. The company has also entered into an amendment and forbearance agreement with respect to the outstanding debt held by JGB. Under agreement terms, ObsEva and JGB agreed to apply the $31M cash earlier held as collateral in a control account against the outstanding convertible notes on a pro rata basis, with JGB waiving a 25% prepayment penalty on the early debt retirement. JGB has agreed to forbear for a period of up to three months from enforcing any rights or remedies under the notes. In exchange, $1.5M was added to the outstanding principal balance under the notes, leading to ~$11M of convertible notes outstanding, and the conversion price of the notes was adjusted to a conversion price of $0.26/share. Shares trading 1.6% higher premarket.
Seeking Alpha • Jul 05

ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for the treatment of women with uterine fibroids set for September 13, 2022. Trial results from the phase 3 EDELWEISS 3 study and long-term extension study for endometriosis are expected 2nd half of 2022; Post-treatment follow-up results from extension study expected early 2023. ObsEva SA (OBSV) is a great long-term biotech to own. The reason why I state that is because despite having received regulatory approval in two territories for linzagolix (marketed as Yselty) for the treatment of women with uterine fibroids, the stock still trades at a very low share price. It received approval of this drug for the treatment of this patient population for the European Union and for the United Kingdom. I believe there is long-term potential just based on these approvals. However, there is an ability to further expand the reach of Yselty to the United States. That's because there is a PDUFA date set for September 13, 2022, and that is when the FDA will decide if this drug should be approved for the very same patient population for use in the United States. I believe that the FDA approval may carry more weight compared to the other two regulatory approvals. Not only that, but the biotech won't have to attempt to sell the drug on its own. Instead, it has already been able to establish two partners for specific territories. It established a partnership for Theramex to sell the drug outside of the U.S., Canada, and Asia. The other partnership that was established was with Syneos Health to sell the drug within the United States upon regulatory approval. It is developing Yselty (linzagolix) for another large market indication which is endometriosis as well. With a few regulatory approvals for Yselty, plus another possible one on the way in Q3 of 2022, these are the reasons why I believe that ObsEva is a great long-term biotech to look into. Two Regulatory Approvals With A Third One Being Possible As I noted directly above, ObsEva received regulatory approvals of Yselty for the treatment of women with uterine fibroids in two territories. Uterine fibroids are benign tumors that end up forming in the uterus (womb) of a woman. When I state the term "benign," that means non-cancerous. The thing is that a majority of the time there are no symptoms. However, in certain cases, they can cause severe pain for the patient. There are several symptoms that uterine fibroids can cause, which are: Heavy Menstrual bleeding Prolonged periods Pelvic pain Cramping Urge to urinate One immediate item to point out is that Yselty was explored in uterine fibroid patients with heavy menstrual bleeding. Thus, heavy menstrual bleeding ((HMB)) is one of the symptoms involved with this disease. Some ways to treat this disease are surgeries and medications. Surgeries may involve attempting to go in and remove the uterine fibroids if successful. The other option involves medications. There are two types of medications: SERMs (Selective estrogen receptor modulators) - work by changing estrogen levels in the body and holds the ability to shrink fibroids without causing menopause symptoms GnRH agonist - GnRH is a type of hormone that a person's body makes naturally. These agonist drugs act as a counter to the production of the GnRH hormone. Thus, in turn it is able to shrink fibroids and sometimes can even reduce anemia as well There are many other additional types of surgeries as well, like cutting off the blood supply to kill the fibroid off. The thing is that the uterine fibroids market is a large one. Well, it only treats women and it is just benign fibroids that are being formed in the uterus. Yes, but believe it or not it is indeed a major problem. Just in the United States alone, it is expected that the uterine fibroids treatment market is estimated to be worth $298.5 million by the end of 2027. One of the first regulatory approvals was achieved back on June 22, 2022, from the European Commission ((EC)). This approval was followed by a positive opinion from the Committee Medicinal Products for Human Use of the European Medicines Agency back in April of 2022. Then, the biotech was able to receive UK Medicines and Healthcare Products Regulatory Agency ((MHRA)) approval of Yselty for this very same patient population. The reason why Yselty was approved was because of positive results from the two phase 3 PRIMROSE studies that were done. It was noted from 24 weeks that there were huge response rates. The breakdown of such response rates is as follows: A responder rate of 84.5% in women who received 200 mg linzagolix with hormonal add back therapy ((ABT)) A responder rate of 56.5% in women who received 100 mg of linzagolix without ABT These two response rates, plus safety profile of the drug, is what allowed for these regulatory approvals. However, where I believe ObsEva may have a competitive advantage is that Yselty is the first drug approved for this specific patient population that gives women the option to be treated without the need for hormone therapy. The need for a drug like Yselty now is to help a woman either delay or avoid the need for surgery altogether. There is potential to expand regulatory approval of Yselty to the United States with the upcoming FDA decision in the 2nd half of 2022. A Prescription Drug User Fee Act ((PDUFA)) date has been established with an action date of September 13, 2022. Agreement has been made in partnership with Theramex to sell Yselty outside of the U.S., Canada and Asia. Another agreement had been made with Syneos Health to sell the drug in the United States upon regulatory approval. Financials According to the 6-K SEC Filing, ObsEva had cash and cash equivalents of $57.6 million as of March 31, 2022. It has been able to raise cash through several different methods over the years. It raised about $5.7 million of net cash in Q1 of 2022 using its at-the-market offering program. Then, made $8.3 million in proceeds from its securities purchase agreement with JGB Management. Speaking of which, this JGB Securities Purchase Agreement is structured to provide about $135 million in borrowing capacity in nine tranches. The first and second tranche were achieved, October 2021 and then January 2022 respectively.

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de OBSE.F han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de OBSE.F han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de ObsEva vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de OBSE.F con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (OBSE.F)n/a
Suelo de mercado 25% (US)1.4%
Techo de mercado 25% (US)4.2%
Media de la industria (Biotechs)2.4%
Analista de previsiones (OBSE.F) (hasta 3 años)n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de OBSE.F en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de OBSE.F en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de OBSE.F para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que OBSE.F no ha comunicado ningún pago.

Descubre empresas que pagan buenos dividendos

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/22 21:08
Precio de las acciones al final del día2026/05/22 00:00
Beneficios2023/06/30
Ingresos anuales2022/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

ObsEva SA está cubierta por 9 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Nathan WeinsteinAegis Capital Corporation
Mayur SomaiyaBMO Capital Markets Equity Research
Edward NashCanaccord Genuity